You just read:

DURECT Announces Presentation of Data from a Phase 1b Study of DUR-928 in Nonalcoholic Steatohepatitis (NASH) at The International Liver Congress™ 2017

News provided by

DURECT Corporation

Apr 24, 2017, 08:00 ET